← Daily Brief
The Bell BriefFrom Dr. Jennifer Bell, DDS
HIGHResearchTier 1

Use of liquid platelet‐rich fibrin (liquid PRF) in temporomandibular joint disorders: A narrative review with clinical recommendations

SourcePeriodontology 2000Tier 1Peer-Reviewed Research

By Nima Farshidfar, Mohammad Amin Amiri, Nathan E. Estrin, Paras Ahmad, Yufeng Zhang, Anton Sculean, Richard J. Miron

Originally at onlinelibrary.wiley.com

Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.

Why it matters for dental

Periodontists, oral surgeons, and TMJ-focused clinicians may see improved non-surgical outcomes and reduced opioid prescriptions by adopting liquid PRF injections for temporomandibular joint disorders, as outlined in the October 2025 Periodontology 2000 narrative review.

Key points

  • Liquid PRF is described as an autologous, chair-side injectable that can be prepared in minutes without anticoagulants, potentially lowering material and inventory costs.
  • The review aggregates clinical evidence showing pain reduction and improved maximum mouth opening at 3- and 6-month follow-ups in patients with Wilkes stage II-III TMJ internal derangement.
  • Authors recommend a standardized protocol: 3–4 ml liquid PRF injected into the superior joint space under ultrasound or arthroscopic guidance, with repeat dosing at 2–4 week intervals.
  • No serious adverse events were reported across the reviewed trials, supporting use in medically complex or anticoagulant-treated patients where NSAIDs or corticosteroids may be contraindicated.

Who should care

SpecialistAcademia

Read the original on Periodontology 2000

Full reporting and any paywall content live on onlinelibrary.wiley.com. We summarize and score; we do not republish.

Open original

Related